Stock Events

Stock Events

Sutro Biopharma 

€20.4
0
+€0.4+2% Wednesday 07:16

Statistics

Day High
20.4
Day Low
20.4
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
1.74B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2025
Q4 2025
Next
-7.03
-5.49
-3.96
-2.43
Expected EPS
-2.4252953439
Actual EPS
N/A

Financials

-366.54%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
117.94MRevenue
-432.29MNet Income

Analyst Ratings

$25.23Average Price Target
The highest estimate is 41.73.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
25%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow S090.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Adaptive Biotechnologies
ADPT
Mkt Cap2.64B
Adaptive Biotechnologies focuses on immune-driven medicines, directly competing in the biopharma space with similar technological approaches as Sutro Biopharma.
Xencor
XNCR
Mkt Cap994.24M
Xencor operates in the development of engineered monoclonal antibodies, a direct competitor to Sutro's antibody-drug conjugate and bispecific antibody platforms.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics focuses on allogeneic CAR T cell therapies, competing in the innovative cancer treatment space alongside Sutro Biopharma.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is engaged in gene editing, a cutting-edge technology that competes with Sutro's platform for developing cancer and autoimmune therapies.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a broad portfolio that includes advanced biopharmaceuticals, competing across multiple areas including oncology, where Sutro is active.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on rare diseases using advanced biotechnologies, competing for similar patient populations and biotech innovation space as Sutro.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is known for its monoclonal antibodies and other biopharmaceuticals, directly competing in the therapeutic areas targeted by Sutro Biopharma.
AMGEN
AMGN
Mkt Cap160.66B
Amgen, a biotechnology pioneer, competes across a range of therapeutic areas, including oncology and inflammation, overlapping with Sutro's focus areas.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, with its strong focus on antiviral drugs and cancer therapies, competes in the development of innovative treatments in areas that overlap with Sutro Biopharma's interests.

About

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Show more...
CEO
Ms. Jane Chung R.Ph.
Employees
137
Country
US
ISIN
US8693672011
WKN
000A41VMF

Listings

XNAS
US
STRO
F
DE
S090.F
BOATS
BOATS
STRO.BOATS

0 Comments

Share your thoughts

FAQ

What is Sutro Biopharma stock price today?▼
The current price of S090.F is €20.4 EUR — it has increased by +2% in the past 24 hours. Watch Sutro Biopharma stock price performance more closely on the chart.
What is Sutro Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Sutro Biopharma stocks are traded under the ticker S090.F.
What is Sutro Biopharma market cap?▼
Today Sutro Biopharma has the market capitalization of 1.74B
When is the next Sutro Biopharma earnings date?▼
Sutro Biopharma is going to release the next earnings report on May 13, 2026.
What were Sutro Biopharma earnings last quarter?▼
S090.F earnings for the last quarter are -4.56 EUR per share, whereas the estimation was -7.03 EUR resulting in a +35.19% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Sutro Biopharma revenue for the last year?▼
Sutro Biopharma revenue for the last year amounts to 117.94M EUR.
What is Sutro Biopharma net income for the last year?▼
S090.F net income for the last year is -432.29M EUR.
How many employees does Sutro Biopharma have?▼
As of April 04, 2026, the company has 137 employees.
When did Sutro Biopharma complete a stock split?▼
The last stock split for Sutro Biopharma was on December 03, 2025 with a ratio of 1:10.
Where is Sutro Biopharma headquartered?▼
Sutro Biopharma is headquartered in South San Francisco, US.